# LINKER-AL2 (NCT06292780)

> A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis)

No report yet. It can be ordered.

- Drugs tested: linvoseltamab
- Indication: relapsed or refractory systemic light chain amyloidosis

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06292780
- Phase: PHASE1, PHASE2
- Status: RECRUITING
- Sponsor: Regeneron Pharmaceuticals
- Conditions: Relapsed/Refractory Systemic Light Chain Amyloidosis
- Interventions: Linvoseltamab
- Enrollment: 220
- Primary outcome: Incidence of dose-limiting toxicity (DLTs)
- Primary outcome: Achievement of hematologic complete response (CR) as determined by the Independent Review Committee (IRC)

## Indexed commentary on LINKER-AL2 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 10
- YouTube: 3
- Podcasts: 1

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=linker-al2-nct06292780

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT06292780", "email": "<work email>"}; the inbox owner confirms by the emailed link.